Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614
with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614
in combination with either nivolumab or nivolumab+ipilimumab immunotherapy in patients with
selected advanced solid tumors. The Phase II portion will estimate the efficacy of ARRY-614
in combination with either nivolumab or ARRY-614 + nivolumab+ipilimumab immunotherapy in
patients with with NSCLC, HNSCC, melanoma and RCC and melanoma.